ASTRAZENECA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,428 GBX | -0.66% |
|
-1.37% | +17.25% |
| 06:16pm | European Equities Close Mixed in Monday Trading; UBS Sued by Russian-Uzbek Billionaire Usmanov | MT |
| 04:09pm | Global markets live: AstraZeneca, Apple, Meta, Microsoft, Cisco... |  |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
2024-07-25
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
158.6
USD
Average target price
174.4
USD
Spread / Average Target
+9.95%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +17.25% | 246B | |
| +52.31% | 791B | |
| +40.45% | 630B | |
| +17.07% | 328B | |
| +9.30% | 298B | |
| +0.41% | 225B | |
| +10.22% | 218B | |
| +4.69% | 160B | |
| -6.15% | 156B | |
| -2.33% | 116B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca's Lung Cancer Drug Shows Clinically Meaningful Improvement in Overall Survival
